Hypertension:慢性肾病患儿舒张功能与动态高血压

2021-10-08 MedSci原创 MedSci原创

与单独的诊室血压相比,动态血压可更好地识别伴有亚临床心功能障碍风险的慢性肾病儿童。

舒张功能障碍是慢性肾病患者最早出现的心脏异常之一。

近日,血管权威杂志Hypertension上发表了一篇研究文章,研究人员旨在分析儿童慢性肾病(CKiD)队列中786名儿童和青少年(1658人次随访)左心室功能超声心动图标志物,CKiD研究是一项针对慢性肾病儿童的大型前瞻性观察研究。

该研究的主要结局是作为左心室顺应性标志物的早期二尖瓣流入速度与早期二尖瓣环峰值速度(E/e')比值。舒张功能异常定义为E/e′>8.0。

与E/e'正常的儿童相比,E/e'比值异常的儿童年龄更小,估计的肾小球滤过率和血红蛋白水平更低,高血压和左心室肥厚的患病率更高。在调整后的分析中,较高的E/e'比值与动态(持续)高血压独立相关(1.66[95%CI为1.15-2.42])。其他显著的独立预测因素是左心室质量指数Z评分较高、体重指数Z评分增加、血红蛋白较低、血磷水平较高和年龄较小。普通血压与较高的E/e'没有显著相关性。

这些数据表明,与单独的诊室血压相比,动态血压可更好地识别伴有亚临床心功能障碍风险的慢性肾病儿童。

原始出处:

Mark M. Mitsnefes.et al.Diastolic Function and Ambulatory Hypertension in Children With Chronic Kidney Disease.Hypertension.2021.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.121.17449

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2026173, encodeId=9e7820261e30a, content=<a href='/topic/show?id=c2968658593' target=_blank style='color:#2F92EE;'>#舒张功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86585, encryptionId=c2968658593, topicName=舒张功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jan 23 23:54:56 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729140, encodeId=dc101e29140bc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Apr 15 09:54:56 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039280, encodeId=498d20392800b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 10 19:54:56 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501552, encodeId=ff10150155264, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Oct 10 11:54:56 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058793, encodeId=57041058e93ee, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sat Oct 09 07:10:47 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2022-01-23 yahu
  2. [GetPortalCommentsPageByObjectIdResponse(id=2026173, encodeId=9e7820261e30a, content=<a href='/topic/show?id=c2968658593' target=_blank style='color:#2F92EE;'>#舒张功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86585, encryptionId=c2968658593, topicName=舒张功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jan 23 23:54:56 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729140, encodeId=dc101e29140bc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Apr 15 09:54:56 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039280, encodeId=498d20392800b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 10 19:54:56 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501552, encodeId=ff10150155264, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Oct 10 11:54:56 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058793, encodeId=57041058e93ee, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sat Oct 09 07:10:47 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2022-04-15 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2026173, encodeId=9e7820261e30a, content=<a href='/topic/show?id=c2968658593' target=_blank style='color:#2F92EE;'>#舒张功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86585, encryptionId=c2968658593, topicName=舒张功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jan 23 23:54:56 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729140, encodeId=dc101e29140bc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Apr 15 09:54:56 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039280, encodeId=498d20392800b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 10 19:54:56 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501552, encodeId=ff10150155264, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Oct 10 11:54:56 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058793, encodeId=57041058e93ee, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sat Oct 09 07:10:47 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2026173, encodeId=9e7820261e30a, content=<a href='/topic/show?id=c2968658593' target=_blank style='color:#2F92EE;'>#舒张功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86585, encryptionId=c2968658593, topicName=舒张功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jan 23 23:54:56 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729140, encodeId=dc101e29140bc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Apr 15 09:54:56 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039280, encodeId=498d20392800b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 10 19:54:56 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501552, encodeId=ff10150155264, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Oct 10 11:54:56 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058793, encodeId=57041058e93ee, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sat Oct 09 07:10:47 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2026173, encodeId=9e7820261e30a, content=<a href='/topic/show?id=c2968658593' target=_blank style='color:#2F92EE;'>#舒张功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86585, encryptionId=c2968658593, topicName=舒张功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sun Jan 23 23:54:56 CST 2022, time=2022-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729140, encodeId=dc101e29140bc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Apr 15 09:54:56 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039280, encodeId=498d20392800b, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue May 10 19:54:56 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501552, encodeId=ff10150155264, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sun Oct 10 11:54:56 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058793, encodeId=57041058e93ee, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sat Oct 09 07:10:47 CST 2021, time=2021-10-09, status=1, ipAttribution=)]
    2021-10-09 学医无涯

    了解一下

    0

相关资讯

JAHA:西藏人群代谢危险因素与左室舒张功能的相关性研究

在高海拔和低氧环境下生活的人中,关于代谢危险因素聚类的左心室舒张功能障碍(LVDD)风险的数据尚缺乏。本研究的目的旨在中国西藏人群中探究代谢危险因素与LVDD的相关性。本研究纳入了1963名西藏人群,平均年龄51.51岁,男性占41.11%。其中LVDD的发病率为34.39%,1个危险因素、2个危险因素和3-5个危险因素的LVDD的风险比分别为1.45 (0.96–2.17), 2.68 (1.8

JAMA Pediatr:成年后左心室结构和舒张功能与儿童期社会经济地位的关系

研究认为,对于家庭社会经济地位较低的儿童,其30年后心血管系统的相关疾病风险较大,该结果强调心血管疾病的预防有必要从儿童时期开展

Hepatology:心血管参数独立预测肝硬化患者的死亡风险

研究表明,经过长期随访,MELD、年龄和BSA是肝硬化患者死亡的主要预测因素。在心血管参数方面,左心房增大,心率增加,E/e',平均血压降低,是死亡独立的预测因素。

心脏再同步化治疗还能一定程度改善心衰患者舒张功能

来源:医学论坛网   心脏再同步化治疗(CRT)是利用心脏起搏技术使心脏失同步达到再同步化,多个临床试验证实 CRT 能提高患者心脏收缩功能,但目前 CRT 对左室舒张功能的疗效尚有争议。沈阳军区总院全军心血管病研所评价了22例接受CRT治疗病例,认为心脏再同步化治疗在一定程度上能够改善心衰患者左房大小及左室舒张末容积进而改善心衰患者的舒张功能。    目前评价左室舒张功能较常用的方

Eur Respir J:持续气道正压通气对左室舒张功能的影响!

由此可见,在重度OSA患者中,CPAP治疗3个月可以显著改善左室舒张功能,相比于假治疗,并且可以同时改善动脉硬化和心室血管耦合。